×
Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematolo...
https://www.ncbi.nlm.nih.gov/pubmed/32720925
Clinical Advances in Hematology & Oncology : H&O;

Apr 30th, 2019 - Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting.|2019||

Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematolo...
https://www.ncbi.nlm.nih.gov/pubmed/32720926
Clinical Advances in Hematology & Oncology : H&O; Locke FL

Apr 30th, 2019 - Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting: Commentary.|2019|Locke FL,|

New CMS Hospital Rule Seeks More Pay for CAR-T, Some Devices
https://www.staging.medscape.com/viewarticle/912218

Apr 24th, 2019 - The Centers for Medicare & Medicaid Services (CMS) is proposing, through a new Medicare hospital payment rule, to provide extra money for certain newer medical products, including costly bioengineered chimeric antigen receptor T-cell (CAR-T) treatments for blood cancers. CMS on Tuesday released the draft fiscal 2020 Inpatient Prospective Payment System rule, which would increase reimbursement f...

New CMS Hospital Rule Seeks More Pay for CAR-T, Some Devices
https://www.medscape.com/viewarticle/912218

Apr 24th, 2019 - The Centers for Medicare & Medicaid Services (CMS) is proposing, through a new Medicare hospital payment rule, to provide extra money for certain newer medical products, including costly bioengineered chimeric antigen receptor T-cell (CAR-T) treatments for blood cancers. CMS on Tuesday released the draft fiscal 2020 Inpatient Prospective Payment System rule, which would increase reimbursement f...

Early Studies of Two Regimens Show Benefit in High-Risk Smoldering Multiple Myeloma
https://ascopost.com/issues/april-25-2019/regimens-show-benefit-in-high-risk-smoldering-multiple-myeloma/

Apr 24th, 2019 - MORE DATA are in to support early intervention for high-risk smoldering multiple myeloma—an early, asymptomatic entity lacking the presence of CRAB criteria (elevated calcium, renal failure, anemia, bone lesions). The latest come from two phase II studies presented at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, which built upon the backbone of lenalidomide plus de...

New Model May Improve Prediction of Risk in Myelodysplastic Syndromes
https://ascopost.com/issues/april-25-2019/new-model-may-improve-prediction-of-risk-in-myelodysplastic-syndromes/

Apr 24th, 2019 - A PERSONALIZED risk-prediction model for myelodysplastic syndromes (MDS) has been developed through the use of a machine-learning approach that analyzes genomic and clinical data for an individual patient. According to lead investigator Aziz Nazha, MD, of the Cleveland Clinic, the model provides survival estimates at different time points, predicts for transformation, and outperforms current mo...

Expert Point of View: High-Risk Smoldering Multiple Myeloma
https://ascopost.com/issues/april-25-2019/epov-smoldering-myeloma/

Apr 24th, 2019 - IN SPITE of the high response rates and lack of progression to active disease with the regimens described at the 2018 American Society of Hematology Meeting & Exposition, several myeloma experts interviewed by The ASCO Post said the data do not yet move them to routinely intervene in high-risk smoldering disease, largely because the studies are small and lack controls. Several experts also poin...

Robert A. Kyle, MD, Luminary in Myeloma Research: Journey From a One-Room Schoolhouse to Groundbreaking Research
https://ascopost.com/issues/april-25-2019/robert-kyle-luminary-in-myeloma-research/

Apr 24th, 2019 - Jame Abraham, MD, FACP In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, interviewed multiple myeloma pioneer Robert A. Kyle, MD, whose groundbreaking work has changed the practice of hematology. Among his many honors are the David A. Karnofsky Memorial Award from ASCO and the Wallace H. Coulter Award from the American Society of Hematology. They are the highest ho...

Emerging translational science discoveries, clonal approaches, and treatment trends in ...
https://doi.org/10.1002/hon.2622
Hematological Oncology REFERENCES; Mughal TI, Pemmaraju N et. al.

Apr 23rd, 2019 - The 60th American Society of Hematology (ASH) held in San Diego in December 2018 was followed by the 13th Post-ASH chronic myeloproliferative neoplasms (MPNs) workshop on December 4 and 5, 2018. This closed annual workshop, first introduced in 2006 by Goldman and Mughal, was organized in collaboration with Alpine Oncology Foundation and allowed experts in preclinical and clinical research in th...

CDC: Opioids OK for People With Cancer and Sickle Cell Disease
https://www.ashclinicalnews.org/online-exclusives/cdc-opioids-okay-people-cancer-sickle-cell-disease/

Apr 18th, 2019 - The Centers for Disease Control and Prevention (CDC) has clarified its 2016 guidelines for opioid prescription, stating that the recommendations were not intended to deny the pain medications to patients with cancer- or sickle cell disease–related pain. Three years ago, the CDC issued the guidelines in response to the growing opioid epidemic; it asked primary-care clinicians to rein in prescrip...

ASCO/ASH Offer Guidance on Anti-Anemia Drugs
https://www.medpagetoday.com/hematologyoncology/hematology/79297

Apr 17th, 2019 - Patients with chemotherapy-associated anemia and whose cancer treatment is not curative in intent may receive erythropoiesis-stimulating agents (ESAs) to raise serum hemoglobin (HgB) to ≥10 mg/dL, according to an updated clinical guideline. Red blood cell (RBC) transfusion also is an option for such patients, as recommended by a panel representing the American Society of Clinical Oncology (ASCO...

ASCO and ASH Release Update to Clinical Practice Guidelines for Use of Erythropoiesis-Stimulating Agents
https://ascopost.com/News/59951

Apr 16th, 2019 - ASCO and the American Society of Hematology (ASH) have released an update to existing guidelines for the use of erythropoiesis-stimulating agents to manage anemia in patients with cancer. The update was simultaneously published in the Journal of Clinical Oncology and Blood Advances. “The current update aims to increase awareness of recent developments regarding the use of erythropoiesis-stimula...

ASCO/ASH Clinical Practice Update: Erythropoiesis-stimulating agents
https://www.mdedge.com/hematology-oncology/article/198888/patient-survivor-care/asco/ash-clinical-practice-update?channel=39313
Caleb Rans

Apr 15th, 2019 - Erythropoiesis-stimulating agents (ESAs) may be offered to patients with chemotherapy-associated anemia whose cancer treatment is not curative in intent and whose hemoglobin (HgB) has declined to less than 10 g/dL, according to a clinical practice guideline update by the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH). Furthermore, ESAs should not be offere.

CDC clarifies opioid prescribing guidelines in cancer, sickle cell disease
https://www.mdedge.com/hematology-oncology/article/198865/patient-survivor-care/cdc-clarifies-opioid-prescribing-guidelines?channel=39313
Alicia Gallegos

Apr 15th, 2019 - Officials at the Centers for Disease Control and Prevention have clarified the agency’s guidelines on opioid prescribing after a trio of organizations raised concerns that insurers were inappropriately applying the recommendations to active cancer patients when making coverage determinations. Dr.

FDA Pipeline: Designation in Uveal Melanoma, Application for MDS Side-Effect Management
https://ascopost.com/News/59933

Apr 11th, 2019 - Over the past week, the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to a treatment for metastatic uveal melanoma and received a biologics application for an agent to control anemia. Fast Track Designation for Tebentafusp in Metastatic Uveal Melanoma The FDA granted Fast Track designation for tebentafusp in the treatment of patients who are HLA-A*0201–positive with p...

Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482353
Blood Advances; Bohlius J, Bohlke K et. al.

Apr 11th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ES...

Venetoclax in the treatment of chronic lymphocytic leukemia.
https://doi.org/10.1080/17425255.2019.1606211
Expert Opinion on Drug Metabolism & Toxicology; Korycka-Wolowiec A, Wolowiec D et. al.

Apr 10th, 2019 - Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for the treatment of relapsed/refractory CLL with del17p, and by the EMA for patients with del17p/TP53 mutation who have failed a BCR inhibitor, or in patients without those aberrations who have failed previous therapy, regardless of their...

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH...
https://doi.org/10.1200/JCO.18.02142
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bohlius J, Bohlke K et. al.

Apr 10th, 2019 - To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs) and meta-analyses of RCTs in patients with cancer published from January 31, 2010, through May 14, 2018. For biosimilar ES...

Allogeneic Hematopoietic Cell Transplantation and Cell Therapy
https://ascopost.com/issues/april-10-2019/allogeneic-hematopoietic-cell-transplantation-and-cell-therapy/

Apr 9th, 2019 - Syed Ali Abutalib, MD Navneet Majhail, MD, MS As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition, here is an update on several studies of allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapy, as used in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (C...

CDC Clarifies Opioid Prescribing Guideline
https://www.medpagetoday.com/painmanagement/opioids/79111?comment=true

Apr 9th, 2019 - ATLANTA -- Clinicians who prescribe opioids to control chronic pain in cancer patients, palliative care, and end-of-life care should follow recommendations of clinical practice guidelines specific to the settings, according to the CDC. Pain management in cancer, palliative care, and end-of-life care involves "unique therapeutic goals and balance of risks and benefits with opioid therapy," Debor...